Furthermore, PT217 exhibits regular mAb-like manufacturability in process development and CMC. We expect to initiate a phase 1 trial to target SCLC in the first half of 2022.
over 2 years ago
IO biomarker
|
CD47 (CD47 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • SIRPA (Signal Regulatory Protein Alpha)